Equities

Nuformix PLC

NFX:LSE

Nuformix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.23
  • Today's Change-0.01 / -4.17%
  • Shares traded57.31m
  • 1 Year change212.29%
  • Beta2.4629
Data delayed at least 20 minutes, as of Feb 06 2026 16:00 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Nuformix PLC had revenues remain flat at 0.00, though the company grew net income from a loss of 3.64m to a smaller loss of 652.59k.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-65.61%
Return on equity-88.76%
Return on investment-88.76%
More ▼

Cash flow in GBPView more

In 2025, Nuformix PLC increased its cash reserves by 382.68%, or 77.34k. Cash Flow from Financing totalled 691.95k or -- of revenues. In addition the company used 614.61k for operations while cash used for investing totalled .
Cash flow per share--
Price/Cash flow per share--
Book value per share0.0004
Tangible book value per share-0.00006
More ▼

Balance sheet in GBPView more

Nuformix PLC uses little or no debt in its capital structure.
Current ratio0.5156
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.